Labaran Waya

Mara lafiya na Farko a Gwajin Lafiya don Ciwon Ƙafafun Ƙafafun Ciwon Ciwon Jiki

Written by edita

Lakewood-Amedex, Inc. ya sanar a yau cewa ya fara nazarin mataki na biyu na biyu ta hanyar amfani da Bisphosphocin Nu-2 antimicrobial wajen magance marasa lafiya da ciwon ƙafar ƙafar ciwon sukari (DFU). Fiye da manya miliyan 3 a Amurka suna da ciwon sukari mellitus (Source: CDC), kuma rikice-rikice na DFU suna da alhakin kusan kashi 34% na yanke kasusuwa marasa rauni a kowace shekara, haifar da mummunar cuta, mace-mace, da nauyi na kuɗi. tsarin kiwon lafiya.

Nazarin Phase 2 shine bazuwar, cibiyar da yawa, makafi biyu, mai sarrafa wuribo, nazarin haɓaka kashi-kashi don kimanta aminci da juriya na gel ɗin Bisphosphocin Nu-3 da aka yi amfani da shi akan Nau'in I ko II masu ciwon sukari mellitus tare da DFU na kullum. A duk lokacin ziyarar asibiti, za a bincika gyambon marasa lafiya don kowane canje-canje a wurin kuma za a tantance zurfin ƙwayar miki da ƙwayoyin cuta.

Steve Parkinson, Shugaba & Shugaba na Lakewood-Amedex, ya ce, "Mun yi matukar farin ciki da fara gwajin mu na asibiti na biyu wajen kula da DFUs. A cikin kwarewarmu da ta gabata ta kimanta Nu-3 don kula da marasa lafiya da ke fama da ciwon ƙafar ƙafar ciwon sukari, Nu-3 ya kasance mai jurewa da kyau ba tare da rahoton wani mummunan lamari da ya shafi jiyya ba. Duk da yake wannan binciken da ya gabata na haɓaka ƙarar ba a ba shi iko don samar da ingantaccen ingantaccen bayanai na ƙididdiga ba, ya nuna haɓakar tasiri mai ƙarfafawa. Marasa lafiya da aka bi da maganin Nu-2 na 3% na kwanaki bakwai sun sami raguwar kashi 65.5% a yankin ulcer tare da raguwar 29.9% a cikin hannun placebo, kamar yadda aka auna kwanaki 14 bayan fara jiyya. Bugu da ƙari, 62.5% na marasa lafiya da aka bi da su tare da 2% Nu-3 sun ga raguwa a cikin nauyin kwayoyin halitta, fiye da 20% a cikin placebo. Yanzu binciken mu na kashi na 2 na haɓakawa zai gina kan harsashin gwaje-gwajen asibiti da suka gabata ta hanyar yin amfani da tsawon lokaci na magani na kwanaki 28, babban taro na 5% wanda ya biyo bayan 10% Nu-3, da kuma ingantaccen Nu-3. gel formulation, duk abin da muke sa ran zai ba da mafi kyawun bayarwa na Nu-3 da kuma maganin raunuka marasa lafiya. Tasirin cututtukan cututtuka na waje da na tsarin jiki sun kasance babban nauyi akan tsarin kiwon lafiya. Mun yi imanin yunƙurinmu na ci gaba da haɓaka dandalin fasahar fasahar Bisphosphocins na antimicrobial tare da ingantacciyar hanyar magance cututtuka masu tsanani, waɗanda galibi ke haifar da cututtukan ƙwayoyin cuta masu jurewa, duka gram-positive da gram-negative, zai ba masu ba da lafiya damar magance su cikin aminci da inganci. tarin cututtukan ƙwayoyin cuta waɗanda a halin yanzu ke tabbatar da ƙalubale ta amfani da hanyoyin al'ada."

“Dr. Felix Sigal, wanda shine ɗaya daga cikin ƙwararrun ƙwararrun ƙwararru a fannin ceton gaɓoɓin ciwon sukari, yana kan ma'aikata a duka Cibiyar Kiwon Lafiya ta Hollywood Presbyterian da Cibiyar Kiwon Lafiyar Asibitin California. Yana mai da hankali kan kula da raunuka da ceton gaɓoɓin ciwon sukari, yayin da yake neman sha'awar binciken asibiti don ba da damar mafi kyawun hanyoyin magani ga majiyyatan sa. Mun yi farin cikin bayar da rahoton cewa Dokta Sigal yanzu ya sanya majiyyaci na farko a cikin wannan binciken na Phase 2 yana kimanta amfani da gel Nu-3 a cikin maganin ciwon ƙafar ƙafar ciwon sukari, "in ji Sumita Paul, MD, MPH, MBA, Babban Jami'in Lafiya. & Babban Mataimakin Shugaban Bincike & Ci gaba a Lakewood-Amedex Inc. "Za a sami marasa lafiya 12 da aka bi da su tare da gel Nu-3 a kowane ɗayan ƙungiyoyin biyu kuma tare da ƙaramin rukunin da aka yi wa magani."

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...